Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
81.03 USD | -0.84% | -1.71% | -15.96% |
Financials (USD)
Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 15.39B |
---|---|---|---|---|---|
Net income 2024 * | 359M | Net income 2025 * | 495M | EV / Sales 2024 * | 5.37 x |
Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.55 x |
P/E ratio 2024 * |
44.7
x | P/E ratio 2025 * |
31.8
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | -0.84% | ||
1 week | -1.71% | ||
Current month | +0.33% | ||
1 month | -10.18% | ||
3 months | -8.40% | ||
6 months | -3.51% | ||
Current year | -15.96% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 0 M€ | -2.17% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 81.03 | -0.84% | 1,521,244 |
24-05-09 | 81.72 | -0.13% | 1,155,017 |
24-05-08 | 81.83 | -0.91% | 1,288,621 |
24-05-07 | 82.58 | +0.58% | 904,833 |
24-05-06 | 82.1 | -0.41% | 895,206 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.96% | 15.39B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-41.29% | 11.89B | |
-15.50% | 11.91B | |
-11.75% | 11.64B | |
+7.87% | 9.03B | |
-3.16% | 8.62B |
- Stock Market
- Equities
- BMRN Stock